Diabetes, metabolic disease, and telomere length. Issue 2 (February 2021)

• Record Type: Journal Article
• Authors: Cheng, Feifei; Carroll, Luke; Joglekar, Mugdha V; Januszewski, Andrzej S; Wong, Kwun Kiu; Hardikar, Anandwardhan A; Jenkins, Alicia J; Ma, Ronald C W
• Is Part Of: Lancet. Volume 9:Issue 2(2021)
• Page Start: 117
• Page End: 126
• Publication Date: 2021-02
• Subjects: Diabetes -- Periodicals; Endocrinology -- Periodicals; Endocrine glands -- Diseases -- Periodicals; 616.4
• DOI: 10.1016/S2213-8587(20)30365-X
• Languages: English
• ISSNs: 2213-8587

Abstract

Summary: Telomeres are regions of repetitive nucleotide sequences at the ends of chromosomes. Telomere length is a marker of DNA damage, which is often considered a biomarker for biological ageing, and has also been linked with cardiovascular disease, diabetes, and cancer. Emerging studies have highlighted the role of genetic and environmental factors, and explored the effect of modulating telomere length. We provide an overview of studies to date on diabetes and telomere length, and compare different methods and assays for evaluating telomere length and telomerase activity. We highlight the limitations of current studies and areas that warrant further research to unravel the link between diabetes and telomere length. The value of adding telomere length to clinical risk factors to improve risk prediction of diabetes and related complications also merits further investigation.